Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Overview of Randomized Clinical Trials

Tricoci, Pierluigi; Newby, L Kristin; Hasselblad, Vic; Kong, David F; Giugliano, Robert P; White, Harvey D; Theroux, Pierre; Stone, Gregg W; Moliterno, David J; Van de Werf, Frans; Armstrong, Paul W; Prabhakaran, Dorairaj; Rasoul, Saman; Bolognese, Leonardo; Durand, Eric; Braunwald, Eugene; Califf, Robert M; Harrington, Robert A

doi:10.1161/CIRCOUTCOMES.110.960294

Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes A Systematic Overview of Randomized Clinical Trials

Author:

Tricoci, Pierluigi

Newby, L Kristin ; Hasselblad, Vic ; Kong, David F ; Giugliano, Robert P ; White, Harvey D ; Theroux, Pierre ; Stone, Gregg W ; Moliterno, David J ; Van de Werf, Frans ; Armstrong, Paul W ; Prabhakaran, Dorairaj ; Rasoul, Saman ; Bolognese, Leonardo ; Durand, Eric ; Braunwald, Eugene ; Califf, Robert M ; Harrington, Robert A

Keywords:

glycoprotein iib/iiia inhibitors, non-st-segment elevation acute coronary syndromes, bleeding, meta-analysis, tissue-level perfusion, myocardial-infarction, unstable angina, acc/aha guidelines, routine upstream, reduce mortality, outcomes, tirofiban, receptor, risk, Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, glycoprotein IIb/IIIa inhibitors, non-ST-segment elevation acute coronary syndromes, UNSTABLE ANGINA, MYOCARDIAL-INFARCTION, ACC/AHA GUIDELINES, REDUCE MORTALITY, OUTCOMES, RISK, INTERVENTIONS, METAANALYSIS, BENEFIT, Acetates, Acute Coronary Syndrome, Administration, Cutaneous, Angioplasty, Electrocardiography, Eptifibatide, Hemorrhage, Humans, Peptides, Platelet Aggregation Inhibitors, Platelet Glycoprotein GPIIb-IIIa Complex, Postoperative Complications, Randomized Controlled Trials as Topic, Risk, Survival Analysis, Tirofiban, Tyrosine, 1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services, Cardiovascular System & Hematology, 3201 Cardiovascular medicine and haematology, 4206 Public health

Abstract:

Background-The use of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes (NSTE ACS) has been studied in multiple randomized clinical trials. We systematically reviewed the effect of upstream GP IIb/IIIa inhibitor use in NSTE ACS as reported in published clinical trials.